跳到正文
Generate:Biomedicines· @generate_biomed · X·· 21 天前AI 评分41
AI 导读

GB-4362 Phase 1 研究设计在 10 月 23 日 ESMO 公布,联合 enfortumab vedotin 与 pembrolizumab 治疗晚期尿路上皮癌。GB-4362 旨在中和游离 MMAE(释放载荷),不结合完整偶联物。研究将评估安全性和游离 MMAE 暴露下降,测试治疗限制性神经病变方案。

正文 · 原文

Target the released payload, not the intact drug.

At the @myESMO Congress on Oct. 23, our team presented the Phase 1 study design for GB-4362 with enfortumab vedotin plus pembrolizumab in advanced urothelial cancer. GB-4362 is designed to neutralize free MMAE, the released payload, without binding the intact drug conjugate. The study will assess safety and reduction in free MMAE exposure, testing an approach to treatment-limiting neuropathy.

See the study design → https://generatebiomedicines.com/publications/a-phase-1-study-of-gb-4362-emso-madrid-2026/

来源:Generate:Biomedicines · x.com